With the supportof Medical Research Council Technology (MRCT), Science & Technology Department of Sichuan Province, Sichuan Food & Drug Administration, The Management Committee of Chengdu Hi-tech Industrial Development Zone, Bureau of Economic & Trade Development of Chengdu Hi-Tech Industrial Development Zone, Haisco Pharmaceutical Group Co., Ltd. and Chengdu Diao Group Co., Ltd, (2nd) International Symposium on Major Innovative Medicine Research & Development and Disease Models was successfully held by Sichuan PriMed Bio-tech Group Co., Ltd., Chengdu PriMed HuaYing Bio-tech Co., Ltd. and Chengdu International Biological Industry Town Investment & Development Co., Ltd. in Chengdu on October 10th, 2016.

This symposium focuses on the latest development of first-in-class drug and disease model onnon-alcoholic fatty liver disease and liver fibrosis, diabetic complications,heart failure and cognitive disorder. It is also dedicated to supporting the doctors, executives, professors and researchers of big pharma all over the world to exchange ideas, network, seek partnership overseas, pinpoint andidentify opportunities and global drug R&D market demand, get updated onthe latest breakthroughs in innovative new drugs and explore business development in across cultural environment.

Thorough research on disease mechanism and development of innovative drugs have become hot topics among participants. 14 Experts and researchers from international research institutes and labs including MRCT, Brown University, Chinese Academy of Sciences, West China Hospital of Sichuan University, Third Military Medical University and Macau University of Science and Technology delivered keynotespeeches concerning non-human primate models and new drug development.

PriMed CEO Dr.Wen Zeng mentioned in her speech: “this international symposium aims to strengthen the international collaboration of medical academic research and new drug development & translation. Development of innovative research results,including new drug development, may cost decades or even longer, which requiresfor the creative strategy of disease mechanism and strategic collaboration ofinnovative drugs translation under new environment of drug R&D to bring Sichuan biomedical industry that PriMed represents in full play on innovative medicine translation and development, bring new energy to Sichuan and China’s biomedical industry as well as bring hopes to millions of patients”.